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Radiobiological rationale for 
stereotactic hypofractionated radiosurgery 
Part I. LQED2 or BED formalism
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Leszek Miszczyk1, Krzysztof Ślosarek4, Marcin Miszczyk4
In conventional radiotherapy, 5R’s mechanisms influence tumour cell kill, but in SHRS they do not sufficiently explain 
the biology of large doses. Indirect cell death is also induced by endothelial damage, stem cell death and antitumour 
immunity are also activated by a single dose ≥ 12–15 Gy. These three processes defined as extra 3R’s are characterizers 
in details. Despite some controversies, LQED formalism seems not quite adequate for SHRS. Experimental and a few 
clinical studies suggest BED formalism as much more useful. Both formalisms are compared and discussed. Clinical 
reports show a monotonical increase in Tumour Cure Probability (TCP) with higher BED doses. The advantage of 
SHRS results in significant shortening overall treatment time and in delivery of the BED doses higher than 100 Gy, 
producing an increase in the TCP, likely unachievable by conventional dose fractionation.
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Stereotactic Hypofractionated Radiosurgery (SHRS) with 
high single dose (i.e. 10–30 Gy) or a few large fractions has 
come to the market as an attractive and highly effective 
method alternative to conventional or altered fractionation 
regimes. It is used not only to irradiate brain tumours, but 
it has been also applied to extracranial tumours [1–4]. The 
results, mainly empirical, show this method to be undoub-
tedly highly effective and well tolerated (Fig. 1). Although 
SHRS is more and more widely applied in practice, it is in 
some way hampered by the still debatable background of 
its radiobiology. 
Radiobiological rationale for SHRS — 5R’s or 8R’s
Five radiobiological processes (5R’s) which regulate cel-
lular malignant and normal tissue response to radiation are 
well recognized. They work in opposite directions, depen-
ding on tumour type and dose fractionation schedules. As 
a response to conventional fractionation redistribution and 
reoxygenation increase cell killing, whereas on the contrary, 
repair and repopulation improve cell survival. 
Considering SHRS, important question arises whether 
the 5R’s are the only mechanisms which decide on final cell 
kill effect of a high single or a few large fractions. Clinical stu-
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dies on SHRS of various primary or metastatic tumour sites 
have documented local tumour control rates significantly 
superior to those achieved by conventional fractionation. 
Therefore, antitumour efficacy of SHRS is greater than wo-
uld be predicted by classic survival curves. Brown et al. [5] 
suggest that in case of SHRS, there are some biological 
challengers to the 5R’s.
Experimental studies [6, 7] have shown that the radio-
sensitivity of tumours to dose fractions of 10 Gy or more is 
governed by the sensitivity of the tumour endothelial cells 
to apoptosis. Park et al. [8] and Song et al. [9] postulate that 
vascular damage induced by high doses indirectly leads 
to tumour cell death. Another study [10] reports enhance-
ment of antitumour immunity by doses higher than 10 Gy. 
Moreover, tumour hypoxia may also play an important role. 
The cell survival model in Figure 2 illustrates concepts 
proposed by Park [8], Brown [5] and Song [9]. The combi-
nation of three survival curves suggests that the cellular 
response to a single dose of 0–5 Gy is likely dominated by 
oxic cells, whereas in the range of 5–12 Gy it is rather do-
minated by hypoxic cells. Above 12 Gy, the overall survival 
curve sharply straightens downwards, which may likely 
correspond with indirect cell death due to vascular endo-
thelial cell damage, and enhanced antitumour immunity. 
These mechanisms called an extra 3R’s probably increase 
the antitumour efficacy of high SHRS doses, which cannot 
be simply explained by the classic 5’Rs. 
Kocher et al. simulated a vascular effect after single dose 
of 20 Gy [11]. Park et al. summarized 43 studies on the ra-
diation-induced vascular damage either in human tumours 
or in their xenografts [8]. Both authors concluded that the 
therapeutic effect of SHRS is likely dominantly influenced 
by vascular effects. Large SHRS doses cause severe vascular 
damage and nutritional deprivation of the intratumour mi-
croenvironment which induce indirect tumour cell death. 
Vascular effects mainly occur after doses of at least 12 Gy 
and higher (Fig. 2 and Fig. 3) and they do not necessarily 
accompany direct effects of cell kill but are usually delayed 
and occur at random time between the onset of irradiation 
and about 1 year thereafter. Dose-equivalent vascular effect 
was counted at the level of about 19–23% of total dose. 
Clinical results with SHRS, especially for early-stage I 
non-small cell lung cancer [5, 12] are impressive and show 
high local tumour control, superior to that achieved by co-
nventional fractionation. Although many different single or 
a few large fractions are used nowadays in practice, the im-
portance of the extra 3R’s is still only qualitatively estimated. 
Its quantitation is not simple, and not yet available. Brown et 
al. [5] conclude that more experimental evidence is needed 
to prove an important role of the extra 3R’s in increasing 
tumour sensitivity and its response to high dose fractions. 
It is generally well recognized that hypoxic cells are more 
radioresistant than oxic ones and likely tumour hypoxia is a 
detrimental factor for SHRS. Within the hierarchy of tumour 
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Figure 1. Local tumor control (TCP) for conventional altered and stereotactic hypofractionated radiotherapy related to Dose Intensity (number of 
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cells, there is a selected subpopulation which is capable of 
self-renewal, and these are called stem cells, being more 
radioresistant than others [13, 14]. There is still a belief in 
rather than evidence of higher radioresistance of the stem 
cells, since their characteristics have not yet been quantified. 
Nevertheless, their response to radiation or other cytotoxic 
agents share with other factors an impact on SHRS clinical 
outcome. 
Ch’ang et al. [15] have shown that at very high doses 
of more than 17–18 Gy, a radiation threshold is crossed 
and stem cells die due to programmed cell death. It se-
ems reasonable to assume that such a threshold may li-
kely exist in human tumours. Kirkpatrick et al. [16] have 
simulated cell survival curves using a LQ model with 
α = 0.3Gy–1 and β = 0.03Gy–2, including a threshold dose 
for vascular damage. In the present paper, their model is 
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supplemented by adding an anticipated effect of antitu-
mour immunity and stem cell death (Fig. 3). High doses 
evoke immune reactions, which among others, induce an 
increase number of cytotoxic T-cells which help to eradicate 
the response of the primary tumour or distant metastases 
[10]. Kirpatrick et al. [16] argue that the LQ model undere-
stimates radiation cell killing at elevated doses because the 
model predicts a continuous downward bending survival 
curve (due to βd2 term), whereas dose-response data are 
likely linear at doses above 12 Gy (Fig. 4). Finally, the authors 
suggest that the LQ model may be inappropriate to design 
SHRS fraction doses, arguing that clinical response to radio-
therapy does not only reflect α and β effects.
LQED2 and BED formalisms 
The Mechanistic Linear-Quadratic (LQ) model of cell 
killing is commonly used to compare biologically doses of 
two or more regimes of conventional radiotherapy by calcu-
lation of equivalent doses to that if given in 2 Gy fractions. 
This formalism was defined by Fowler [17] as LQED2 (term 
NTD is also used): 
LQED2 = Di (α/β + di) / (α/β + 2.0 Gy) (1)
The LQED2 formalism presumes complete cellular repair 
between fractions and neglects the role of treatment time 
(cellular repopulation). Nevertheless, this formalism pro-
vides a good fit for the majority of conventional external 
radiotherapy.
An alternative approach is based on the assumption 
of a purely theoretical regimen with a total dose delivered 
in an infinitive number of infinitively small fraction doses 
(di) decreasing to di = 0, with complete repair of sublethal 
damage between fractions. Transforming Eq. 1 by setting a 
2.0 Gy, model expresses the biological total dose, defined 
by Fowler [17] as the Biologically Effective Dose (BED) is:
     (2)
where Di and di are total and fraction dose respectively.
However, both the LQED2 and BED formalisms ignore 
effects of inhomogeneous dose distribution within irra-
diated volume.
Although the physical DVH illustrates the proportions of 
the volume receiving dose above or below assumed level, 
it does not illustrate its localization in the anatomical spa-
ce of high-or low-dose regions. “Hot spots” within tumour 
volume are acceptable or even expected, whereas within 
critical normal tissues these can be disastrous, especially in 
organs (e.g. spinal cord) with serial structure, even if they 
are isolated and small. For such structures failure of any 
small element is critical. In contrast, “cold spots” within the 
tumour volume may lead to local failure, or at least to a 
lesser or greater decrease in the predicted probability of 
local tumour control. 
According to Brenner [18], the LQ model seems reasona-
bly predictive for a response to dose per fraction in the range 
of 2 to 18 Gy. Although the model might be progressively 
less accurate above 15 Gy, it could be useful in clinical studies 
within acceptable frames. At very high doses (> 17–18 Gy), 
the threshold is crossed, and tumour stem cells die as a re-
sult of programmed cell death, likewise of vascular damage 
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leading to necrotic death in the majority of tumour cells, 2 
to 3 days after irradiation or a bit later.
Despite some suggestions that LQED2 cannot logically 
work for SHRS (Fig. 4), because 60 Gy in 30 fractions is ab-
solutely not equivalent to 60 Gy in 3 fractions. It is obvious 
that α and β factors in the LQED2 model do not quantitively 
express all biological mechanisms induced by large single or 
fractionated doses. The LQED2 model likely underestimates 
radiation cell killing at higher doses (Fig. 4). The cell survival 
curve above 3–15 Gy becomes largely linear, leading to 
considerably lower surviving fraction than that predicted 
by the LQED2 model. However, until now, there is a lack of 
quantitative data regarding the impact of indirect features 
on the shape and steepness of the tumour cell survival curve.
Is BED formalism favourable for SHRS?
Aside from α and β factors, there is another “handy” and 
attractive radiobiological parameter, defined as eD0, which 
characterizes the exponential part of the cell survival curve. 
In vitro and some clinical studies convincingly document 
the eD0 of about 3.0 Gy for 2.0 Gy fraction regimens. The eD0 
decreases the surviving fraction (SF) to e–1 (this means to 
0.37 of the initial number of tumour cells). However, it is not 
easy to apply eD0 in practice, and the eD10 parameter is more 
practical (Appendix 1) because it results in the decreases of 
cell surviving fraction by one decade of cells (e. q. from 109 
to 108). For the majority of solid tumours, eD10 is about 7 Gy 
(eD10 = 2.3 × eD0). If, for example, TCP of 90% is planned for 
tumour with 1010 cells, then it requires a decrease of the 
surviving fraction to 10–11 (TCP90 = e 
–(1010 ⋅10–11) = e–0.1) and 
the respective total dose in 2.0 Gy fractions would be 11 × 
7 Gy = 77 Gy. However, such an estimation does not work for 
SHRS because the D10 of 7 Gy underestimated cell kill effect. 
Based on the report of 12 NSCLC cell lines from the 
NCI, Park et al. determined mean values for α = 0.33 Gy–1, 
eD0 =  1.23 – 1.65 Gy and Dq = 1.8 Gy, parameters which 
describe the cell survival curve for a large fraction regimen 
with much lower eD0 [8]. Using that eD0 value, we calculate 
a respective eD10 of 2.8–3.8 Gy. Thus, eD10 for large fractions 
seems to about 2-times lower than that for 2 Gy regimens, 
and more effective because 7 Gy in one fraction of SHRS 
would reduce cell survival by two decades, compared with 
one decade of cells reduced by 7 Gy given in 3 fractions of 
conventional regimen. This proves that the LQED2 is not 
really representative for large fractions because it lowers 
its real biological power. 
The majority of large fraction regimens have been de-
signed empirically. Park et al. listed ten various large fraction 
regimens which were used to irradiate patients with early 
stage I of NSCLC [8]. It is difficult to explain why some authors 
use single dose of 10–20 Gy, whereas others prefer 20–34 Gy. 
We used different total physical doses given as a single or 
3–4 fractions to estimate respective BED10, using α/β = 10 Gy 
values. Figure 5 shows that a choice of SHRS regimes is not 
incidental since respective BED10 curves for single, 3 and 
4 fractions give a good linear fit to the BED doses. 
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The BED formalism quite well fits a correlation between 
TCP and the BED values. To demonstrate this relationship, we 
used data from Fowler et al. for intermediate risk prostate 
cancer, to recalculate physical doses as BED2 [19]. Figure 6 
shows the BNED (Biochemical No Evidence of Disease) orig-
inal curve representing a conventional fractionation dose of 
72 Gy in 2 fractions (BED1.5 = 167 Gy1.5) resulting in BNED of 
69%. Instead of increasing the conventionally fractionated 
total dose, large fraction regimens, from 15 × 3.6 Gy to 3 × 
10 Gy reflect an increasing BED2 from 167 Gy1.5 to 230 Gy1.5 
which yields a 28% increase in BNED. Moreover, an import-
ant advantage of SHRS regimens is significant shortening 
of overall treatment time from 50 days to even 3–5 days.
The BED formalism as a version of the LQ model seems 
reliable for the design and comparison of various SHRS 
protocols even for fraction doses higher than 10 Gy. It mi-
ght be naive to believe that the clinical response to SHRS 
depends only on α and β effects. It is much more reasona-
ble to accept that additional indirect 3R’s also participate 
in the response to SHRS, but these need to be validated 
experimentally and clinically. Clinical results show that TCP 
monotonically gets higher with an increase in BED, and the 
clinical benefit of SHRS is noted due to delivery of BED doses 
higher than 100 Gy, which is unachievable by conventional 
dose fractionation. 
Conclusions 
High local efficacy (high TCP) of Stereotactic Hypofrac-
tionated Radiosurgery depends on the direct radiation cell 
kill (5R’s) and additionally on indirect vascular damage, 
stem cells programmed death and antitumour immunity 
(extra 3R’s) which can be counted as about 19–23% of total 
dose. Among LQ formalisms, the BED correlates with SHRS 
efficacy better than LQED2, because its values monotonically 
increase when SHRS single or fractionated doses get higher. 
High clinical efficacy of SHRS can be achieved due to BED 
delivery of doses higher than 100 Gy, which is unachievable 
by conventional dose fractionation.
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Appendix 1 
The slope of the exponential part of cell survival curve is described by effective D0 (eD0).
For dose D dose equals 1eD0:
SF = e–(1eD0/1eD0)    (a)
 = e–1
 = 0.37
Therefore, one eD0 reduces cell survival (SF) to 0.37
The eD0 is not very useful to estimate SF for a multifraction regimen, therefore
if dose D equals 2.3 eD0 then:
SF = e–(2.3eD0/1eD0)    (b)
 = e–2.3
 = 0.1
Thus 2.3 × eD0 reduces cell survival by one decade of cells (i.e. from 10
–2 to 10–1) and it is defined as eD10 and 
eD10 = 2.3 × eD0    (c)
In radiotherapy eD0 for 2.0 Gy fraction regimen is on average ~3.0 Gy. From that 
eD10(2.0 Gy fractions) = 2.3 × 3 Gy = 6.9 Gy ~7 Gy
